Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR
暂无分享,去创建一个
B. Rosen | J. Mandeville | G. Knudsen | C. Catana | J. Hooker | H. D. Hansen | C. Y. Sander | C. Sander
[1] C. Svarer,et al. Serotonin 1B Receptor Binding Is Associated With Trait Anger and Level of Psychopathy in Violent Offenders , 2017, Biological Psychiatry.
[2] Richard Baumgartner,et al. Evaluation of an fMRI USPIO‐based assay in healthy human volunteers , 2017, Journal of magnetic resonance imaging : JMRI.
[3] R. Hargreaves,et al. Challenges in developing drugs for primary headaches , 2017, Progress in Neurobiology.
[4] P. Svenningsson,et al. Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia – An autoradiography study , 2017, European Neuropsychopharmacology.
[5] Ciprian Catana,et al. Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI , 2016, Neuropsychopharmacology.
[6] phMRI: methodological considerations for mitigating potential confounding factors , 2015, Front. Neurosci..
[7] C. Lindsley,et al. New statistics on the cost of new drug development and the trouble with CNS drugs. , 2014, ACS chemical neuroscience.
[8] Lars Farde,et al. Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain , 2014, NeuroImage.
[9] Pradeep J Nathan,et al. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. , 2014, Current opinion in pharmacology.
[10] C. Yokoyama,et al. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques , 2014, Translational Psychiatry.
[11] Gary Glover,et al. Ferumoxytol enhanced resting state fMRI and relative cerebral blood volume mapping in normal human brain , 2013, NeuroImage.
[12] Yiyun Huang,et al. Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABAA-Benzodiazepine Binding with 11C-Flumazenil in Awake and Anesthetized Animals , 2013, The Journal of Nuclear Medicine.
[13] Julian Macoveanu,et al. Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala , 2013, Journal of psychopharmacology.
[14] Ciprian Catana,et al. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI , 2013, Proceedings of the National Academy of Sciences.
[15] Ciprian Catana,et al. PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.
[16] Thomas Christen,et al. Contrast-enhanced functional blood volume imaging (CE-fBVI): Enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol , 2012, NeuroImage.
[17] Joseph B. Mandeville,et al. IRON fMRI measurements of CBV and implications for BOLD signal , 2012, NeuroImage.
[18] Bruce G. Jenkins,et al. Pharmacologic magnetic resonance imaging (phMRI): Imaging drug action in the brain , 2012, NeuroImage.
[19] Paul M. Matthews,et al. Positron emission tomography molecular imaging for drug development. , 2012, British journal of clinical pharmacology.
[20] J. Olesen,et al. Effect of CGRP and sumatriptan on the BOLD response in visual cortex , 2012, The Journal of Headache and Pain.
[21] J. Detre,et al. Potentials and Challenges for Arterial Spin Labeling in Pharmacological Magnetic Resonance Imaging , 2011, Journal of Pharmacology and Experimental Therapeutics.
[22] Ciprian Catana,et al. Toward Implementing an MRI-Based PET Attenuation-Correction Method for Neurologic Studies on the MR-PET Brain Prototype , 2010, The Journal of Nuclear Medicine.
[23] Richard E Carson,et al. High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. , 2010, Nuclear medicine and biology.
[24] Z. Bhagwagar,et al. The 5-HT1B receptor: a novel target for the pathophysiology of depression. , 2009, Current drug targets.
[25] L. Mrzljak,et al. [N-methyl-3H3]AZ10419369 Binding to the 5-HT1B Receptor: In Vitro Characterization and in Vivo Receptor Occupancy , 2009, Journal of Pharmacology and Experimental Therapeutics.
[26] Christer Halldin,et al. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain , 2008, NeuroImage.
[27] P. Boesiger,et al. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI , 2007, Nature Neuroscience.
[28] K. Miczek,et al. Anti-aggressive effects of agonists at 5-HT1B receptors in the dorsal raphe nucleus of mice , 2007, Psychopharmacology.
[29] Yun Zhou,et al. An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge , 2006, NeuroImage.
[30] M. Pomper,et al. Positron emission tomography in molecular imaging , 2004, IEEE Engineering in Medicine and Biology Magazine.
[31] Y. Sari. Serotonin1B receptors: from protein to physiological function and behavior , 2004, Neuroscience & Biobehavioral Reviews.
[32] D. Hoyer,et al. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.
[33] S. Ross,et al. Failure to detect in vivo inverse agonism of the 5-HT1B receptor antagonist SB-224289 in 5-HT-depleted guinea-pigs , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.
[34] D. Middlemiss,et al. SB-236057-A: a selective 5-HT1B receptor inverse agonist. , 2006, CNS drug reviews.
[35] E. Hamel,et al. Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles , 2001, British journal of pharmacology.
[36] J. Williams,et al. Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. , 2000, Molecular pharmacology.
[37] J. Pickard,et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. , 1999, British journal of clinical pharmacology.
[38] L. Descarries,et al. Endothelial expression of the 5-hydroxytryptamine1B antimigraine drug receptor in rat and human brain microvessels , 1998, Neuroscience.
[39] B. Rosen,et al. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation , 1998, Magnetic resonance in medicine.
[40] P. Pauwels,et al. Pharmacological analysis of G‐protein activation mediated by guinea‐pig recombinant 5‐HT1B receptors in C6‐glial cells: similarities with the human 5‐HT1B receptor , 1998, British journal of pharmacology.
[41] J. Palacios,et al. Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[42] S. J. Starkey,et al. GR127935: a potent and selective 5-HT1D receptor antagonist , 1995, Behavioural Brain Research.
[43] M. Geyer. Serotonergic functions in arousal and motor activity , 1995, Behavioural Brain Research.
[44] Cocaine enhancement of the action of 5-hydroxytryptamine in rat cingulate cortex in vitro , 1993, Neuroscience Letters.
[45] B. Rosen,et al. Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.